This may already have been posted but good to see continued strong support from Hashan and Karst Peak who were Neuren's largest holders at $1 and are backing the company to be an attractive M&A target.
https://www.linkedin.com/posts/hashan-de-silva_why-analysts-love-these-eight-medtech-stocks-activity-7163321989502283776-z7Ef?utm_source=share&utm_medium=member_desktop
"Neuren Pharmaceuticals Limited has had a very successful 2 years however we still see considerable upside when looking at comparable transactions. Orphan drugs has been a hot area for a while and with neuroscience coming back into focus for big pharma, we see Neuren as an attractive target for M&A."
- Forums
- ASX - By Stock
- NEU
- Merck to acquire Prometheus in a US$ 10.8 b deal
Merck to acquire Prometheus in a US$ 10.8 b deal, page-92
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.34 |
Change
-0.410(2.60%) |
Mkt cap ! $1.960B |
Open | High | Low | Value | Volume |
$15.88 | $15.93 | $15.34 | $6.463M | 415.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 6044 | $15.32 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.57 | 1411 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1892 | 15.320 |
3 | 2996 | 15.300 |
1 | 1308 | 15.290 |
1 | 300 | 15.280 |
2 | 1892 | 15.270 |
Price($) | Vol. | No. |
---|---|---|
15.570 | 1411 | 2 |
15.620 | 2616 | 3 |
15.660 | 1892 | 1 |
15.680 | 1892 | 1 |
15.710 | 1892 | 1 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online